Tatiana Novobrantseva
Chief Scientific Officer NextPoint Therapeutics
Seminars
Wednesday 20th August 2025
The Story of the B7-H7 Targeting ADC: Exploring a Proprietary Linker for Maximal Compatibility with Targeting Biology
1:30 pm
- Attributes of B7-H7 as a tumor target
- ADC linker approach for addressing the vast B7-H7 positive patient population
- NPX125 linker design and attributes
